Efficacy News and Research

RSS
MagForce Nanotechnologies completes clinical trial of Nano-Cancer therapy in glioblastoma patients

MagForce Nanotechnologies completes clinical trial of Nano-Cancer therapy in glioblastoma patients

Referenced-EEG outperforms STAR*D treatment in depression care

Referenced-EEG outperforms STAR*D treatment in depression care

New strategy to eliminate and eradicate malaria unveiled

New strategy to eliminate and eradicate malaria unveiled

Enobia Pharma initiates study of bone-targeted enzyme replacement therapy for hypophosphatasia

Enobia Pharma initiates study of bone-targeted enzyme replacement therapy for hypophosphatasia

Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease

Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease

MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials

MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials

Malaria Conference addresses RTS,S vaccine, tools, treatment

Malaria Conference addresses RTS,S vaccine, tools, treatment

Financial results for third-quarter 2009 announced by Combinatorx

Financial results for third-quarter 2009 announced by Combinatorx

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint

Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint

Crohn's disease drug market driven by TNF-alpha inhibitors Humira and Remicade

Crohn's disease drug market driven by TNF-alpha inhibitors Humira and Remicade

Efficacy trial of the world's most clinically advanced malaria vaccine candidate underway

Efficacy trial of the world's most clinically advanced malaria vaccine candidate underway

Phase 1 study of STX107 for Fragile X syndrome begins

Phase 1 study of STX107 for Fragile X syndrome begins

NuPathe and SurModics sign a drug delivery technology license agreement

NuPathe and SurModics sign a drug delivery technology license agreement

Top-line results from Phase 3 linaclotide trial for chronic constipation

Top-line results from Phase 3 linaclotide trial for chronic constipation

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

FDA issues a Complete Response Letter for GTx' toremifene NDA

FDA issues a Complete Response Letter for GTx' toremifene NDA

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.